SCHEMBL3962812

SCHEMBL3962812

CCCCCCOc1ccccc1C(C)=O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.74
MAPT P10636 6/20 0.74
CYP3A4 P08684 2/20 0.74
MEN1 O00255 1/20 0.74
NR1I2 O75469 1/20 0.74
CHRM2 P08172 1/20 0.74
ADRA2A P08913 1/20 0.74
OPRK1 P41145 1/20 0.74
HTR2B P41595 1/20 0.74
SLC6A3 Q01959 1/20 0.74
KMT2A Q03164 1/20 0.74
HDAC6 Q9UBN7 1/20 0.74
SMN1; SMN2 Q16637 4/20 0.71
L3MBTL1 Q9Y468 3/20 0.70
ALDH1A1 P00352 4/20 0.68
KDM4E B2RXH2 2/20 0.68
HTT P42858 1/20 0.59
TSHR P16473 2/20 0.58
NPSR1 Q6W5P4 1/20 0.58
PTPN11 Q06124 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10428688 1.00 LMNA (0.74) LMNAMAPTCYP3A4MEN1NR1I2
SCHEMBL15766523 1.00 LMNA (0.74) LMNAMAPTCYP3A4MEN1NR1I2
SCHEMBL11738774 1.00 LMNA (0.74) LMNAMAPTCYP3A4MEN1NR1I2
SCHEMBL524256 0.98 LMNA (0.73) LMNAMAPTCYP3A4MEN1NR1I2
SCHEMBL8154526 0.93 LMNA (0.74) LMNAMAPTCYP3A4MEN1NR1I2
SCHEMBL15154872 0.88 LMNA (0.77) LMNAMAPTCYP3A4MEN1NR1I2
SCHEMBL3135517 0.88 LMNA (0.74) LMNAMAPTCYP3A4MEN1NR1I2
SCHEMBL3665313 0.87 KMT2A (0.74) LMNAMAPTCYP3A4MEN1NR1I2
SCHEMBL168816 0.87 KMT2A (0.74) LMNAMAPTCYP3A4MEN1NR1I2
SCHEMBL18141371 0.87 KMT2A (0.74) LMNAMAPTCYP3A4MEN1NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160221921-A1 SKIN WHITENING AGENT CONTAINING NOVEL CYCLIC COMPOUND RNS CO.,LTD. (KR) 2016-08-04 US disclosed
US-7566737-B2 Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2009-07-28 US disclosed
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2007-02-08 US disclosed
CN-85101534-A The method of curable synthetic resin composition and manufacturing multipolymer 1987-01-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients PSEN1, BACE1, PSEN2 LMNA 1551/4885MAPT 133/4885CYP3A4 3088/4885
US-20160221921-A1 SKIN WHITENING AGENT CONTAINING NOVEL CYCLIC COMPOUND H1-10, HCN1, HCN4 LMNA 494/4885MAPT 4627/4885CYP3A4 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.